Candel Therapeutics' stock rose after receiving FDA orphan drug designation for pancreatic cancer treatment CAN-2409.
Candel Therapeutics stock increased after the company received FDA orphan drug designation for CAN-2409 to treat pancreatic cancer. The treatment showed promising results in a phase 2 clinical trial, with CAN-2409, when added to standard care, more than doubling median overall survival compared to standard care alone. This marks Candel's second significant designation from the FDA, following fast-track designation for the same program.
April 11, 2024
10 Articles